The FDA's Drugs@FDA database lists a supplement dated 7 October 2026 to the new drug application for tucatinib (Tukysa), held by Seagen. The entry gives the application number, company and drug name only. It does not say what the supplement covers.
Supplements can concern labelling, manufacturing or a new indication. This record does not distinguish between them, so it should not be read as an approval of a new use or as a safety communication. If you prescribe tucatinib, check the current prescribing information.
The record says nothing about CDSCO or Indian availability; both are unknown here.
- The entry names the application and the company but not the change.
- It is not stated to be a new indication or a safety warning.
- Check the current prescribing information if you use tucatinib.
- No change in practice follows from this record.
Why it matters
Supplements to an existing application are often administrative, and a clinician needs the label, not the database entry, to know what changed.
Don't overread it
A supplement is not a new indication, and the record does not describe its content.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free